{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:36Z","timestamp":1788883716218,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Children and adolescents with early-stage nodular lymphocyte\u2013predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of \u223c77% after complete lymph node resection and \u223c89% with anthracycline-containing chemotherapy. We investigated whether those patients can be successfully treated with surgical resection alone or with low-intensity, anthracycline-free CVP (cyclophosphamide, vinblastine, and prednisone) chemotherapy. EuroNet-PHL-LP1 was a prospective phase 3 trial enrolling patients aged &amp;lt;18 years with stage IA\/IIA nLPHL. Complete resection led to active surveillance. Patients with unresectable disease received 3 cycles CVP. In CVP cohort 1, treatment cessation required negative 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography (18F-FDG PET). An amendment in 2014 omitted PET for end-of-treatment response; computed tomography and\/or magnetic resonance imaging alone defined response in CVP cohort 2. The primary endpoint was 5-year EFS, with death, relapse, second malignancy, and PET positivity counting as events; for CVP cohort 2, progression-free survival (PFS) was primary. Among 267 registered patients, 247 were evaluable. Seventy-eight underwent resection only; their 5-year EFS\/PFS was 79.5%. Six of 18 patients who relapsed after surgical resection reentered the CVP arm. In CVP cohort 1, 51 of 82 (62%) achieved complete metabolic response (CMR). Five-year EFS was 56.4%, whereas 5-year PFS in the CMR group was 91.3%. In contrast, PFS in 84 patients in CVP cohort 2 was 64.7%. During CVP, 68.3% of patients experienced grade 3 to 4 neutropenia. No treatment-related deaths were reported. Excellent outcomes were achieved after complete resection and with low-intensity, anthracycline-free chemotherapy if in CMR after chemotherapy. This strategy now constitutes the EuroNet-PHL standard of care for early-stage nLPHL. The trial was registered at www.clinicaltrialsregister.eu as EudraCT 2007-004092-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019765","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:53:46Z","timestamp":1780516426000},"page":"5865-5873","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte\u2013predominant Hodgkin lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-5776","authenticated-orcid":false,"given":"Ananth","family":"Shankar","sequence":"first","affiliation":[{"name":"1Children and Young People\u2019s Cancer Services, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Landman-Parker","sequence":"additional","affiliation":[{"name":"2H\u00f4pital Armand-Trousseau, Assistance Publique- Hopitaux de Paris, SIRIC CURAMUS, Sorbonne Universit\u00e9, and Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-0257","authenticated-orcid":false,"given":"Maurizio","family":"Mascarin","sequence":"additional","affiliation":[{"name":"3Department Radiation Oncology and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico IRCCS, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-6898","authenticated-orcid":false,"given":"Andishe","family":"Attarbaschi","sequence":"additional","affiliation":[{"name":"4St. Anna Children\u2019s Hospital, Medical University of Vienna, St. Anna Children\u2019s Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah","family":"Boudjemaa","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Armand Trousseau and Piti\u00e9 Salp\u00eatri\u00e8re University Hospitals, AP-HP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Burnelli","sequence":"additional","affiliation":[{"name":"6Pediatric Hemato-Oncology Unit, Azienda Ospedaliero-Universitaria Sant\u2019Anna, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-1823","authenticated-orcid":false,"given":"Auke","family":"Beishuizen","sequence":"additional","affiliation":[{"name":"7Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"8Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-588X","authenticated-orcid":false,"given":"Michaela","family":"Cepelova","sequence":"additional","affiliation":[{"name":"9Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceppi","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Georgi","sequence":"additional","affiliation":[{"name":"11Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Hall","sequence":"additional","affiliation":[{"name":"12Paediatric Haematology Oncology Unit, Oxford Children\u2019s Hospital, John Radcliffe Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"13Institute for Pathology, Section Haematopathology and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Kluge","sequence":"additional","affiliation":[{"name":"14St. Georg Hospital, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"Egesta","family":"Lopci","sequence":"additional","affiliation":[{"name":"15Dipartimento di Diagnostica per Immagini, IRCCS Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-4611","authenticated-orcid":false,"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[{"name":"16Section of Leukemia and Lymphoma, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Phoenix Children\u2019s Hospital, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-0420","authenticated-orcid":false,"given":"Alan","family":"Ramsay","sequence":"additional","affiliation":[{"name":"17Moorfields Eye Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-1481","authenticated-orcid":false,"given":"Jonas","family":"Steglich","sequence":"additional","affiliation":[{"name":"18Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Stoevesandt","sequence":"additional","affiliation":[{"name":"19Department of Diagnostic and Interventional Radiology, University Hospital Halle, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-4880","authenticated-orcid":false,"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[{"name":"11Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"K\u00f6rholz","sequence":"additional","affiliation":[{"name":"20Department of Paediatric Hematology, Oncology, and Immunodeficiency, Justus Liebig University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-1610","authenticated-orcid":false,"given":"Dirk","family":"Hasenclever","sequence":"additional","affiliation":[{"name":"21Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-8665","authenticated-orcid":false,"given":"Christine","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[{"name":"20Department of Paediatric Hematology, Oncology, and Immunodeficiency, Justus Liebig University Giessen, Giessen, Germany"},{"name":"22Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"5","key":"2026090811315512000_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2026090811315512000_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin's disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811315512000_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol"},{"issue":"9","key":"2026090811315512000_bib4","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2026090811315512000_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026090811315512000_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026090811315512000_bib7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O'Brien","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026090811315512000_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026090811315512000_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2141.2007.06736.x","article-title":"Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report","volume":"138","author":"Hall","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"2026090811315512000_bib10","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/cncr.11807","article-title":"Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi","volume":"98","author":"Gobbi","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"2026090811315512000_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"2026090811315512000_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin's disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"issue":"6","key":"2026090811315512000_bib13","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"18","key":"2026090811315512000_bib14","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026090811315512000_bib15","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2026090811315512000_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2026090811315512000_bib17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026090811315512000_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026090811315512000_bib19","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026090811315512000_bib20","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.23.01655","article-title":"International Prognostic Score for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"42","author":"Binkley","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026090811315512000_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.18169","article-title":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - all StAGEs: a consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","volume":"197","author":"Shankar","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2026090811315512000_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood.2023019939","article-title":"Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies","volume":"142","author":"Eichenauer","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2026090811315512000_bib23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026090811315512000_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00277-015-2578-6","article-title":"A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma","volume":"95","author":"Strobbe","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"2026090811315512000_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.782","article-title":"Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake","volume":"24","author":"Hutchings","year":"2006","journal-title":"Hematol Oncol"},{"issue":"5","key":"2026090811315512000_bib26","doi-asserted-by":"crossref","first-page":"e31606","DOI":"10.1002\/pbc.31606","article-title":"PET response and outcome in low-risk nodular lymphocyte-predominant Hodgkin lymphoma: Children's Oncology Group Study AHOD03P1","volume":"72","author":"Marks","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2026090811315512000_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.bulcan.2023.03.006","article-title":"Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma","volume":"110","author":"Dourthe","year":"2023","journal-title":"Bull Cancer"},{"issue":"2","key":"2026090811315512000_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.13540","article-title":"Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma - a review of clinical outcome based on the histological variants","volume":"171","author":"Shankar","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2026090811315512000_bib29","doi-asserted-by":"crossref","first-page":"e27288","DOI":"10.1002\/pbc.27288","article-title":"Unfavorable presentation but comparable outcome: presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India","volume":"65","author":"Prasad","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026090811315512000_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.26753","article-title":"Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"65","author":"Untanu","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"2026090811315512000_bib31","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1182\/bloodadvances.2023010652","article-title":"Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response","volume":"7","author":"Sereda","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5865\/2541749\/blooda_adv-2026-019765-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5865\/2541749\/blooda_adv-2026-019765-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:05Z","timestamp":1788881525000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5865\/568867\/EuroNet-PHL-LP1-complete-resection-or-low-dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019765","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}